Eli Lilly's weight-loss pill wins EU drug regulator's backing
LLY•The European Medicines Agency's committee recommended approval of Eli Lilly's Foundayo for weight management and treatment of type 2 diabetes in adults. The European Commission will review the recommendation and make the final decision before launch.
1. EU regulator recommendation
The European Medicines Agency's committee recommended granting marketing authorisation for Eli Lilly's Foundayo, making it the second oral weight-loss drug to win the agency's backing after Novo Nordisk's Wegovy pill. The European Commission will review the recommendation and give a final decision before Eli Lilly can launch the drug.
2. Weight-loss drug rivalry
The race to broaden access to oral drugs has become the latest battleground in Novo and Lilly's weight-loss drug rivalry. Both aim to secure a larger share of a market expected to surpass $100 billion by 2030.
